Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary Shares, $0.00001 Par Value
-
Shares outstanding
-
494,239,409
-
Total 13F shares
-
548,421
-
Share change
-
-85,108
-
Total reported value
-
$11,516,841
-
Put/Call ratio
-
200%
-
Price per share
-
$21.00
-
Number of holders
-
17
-
Value change
-
-$1,468,035
-
Number of buys
-
10
-
Number of sells
-
9
Institutional Holders of Regencell Bioscience Holdings Ltd - Ordinary Shares, $0.00001 Par Value (RGC) as of Q4 2025
As of 31 Dec 2025,
Regencell Bioscience Holdings Ltd - Ordinary Shares, $0.00001 Par Value (RGC) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
548,421 shares.
The largest 10 holders included
GEODE CAPITAL MANAGEMENT, LLC, Vident Advisory, LLC, Squarepoint Ops LLC, MORGAN STANLEY, UBS Group AG, XTX Topco Ltd, Hudson Bay Capital Management LP, BlackRock, Inc., Seven Fleet Capital Management LP, and EverSource Wealth Advisors, LLC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.